Synergistic effects of combing proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers
A. M. Rykkelid, P. M. Sinha, C. A. Folefac, M. R. Horsman, B. S. Sorensen, T. M. Soland, O. J. F. Schreurs, E. Malinen, N. F. J. Edin
Abstract
Background and purposeCombining radiation therapy with immunotherapy may be beneficial in treatment of head and neck cancer (HNC), but the combined effect may depend on tumor characteristics and the type of radiation. The purpose was to compare responses for two syngeneic tumor models in mice following X-ray or proton irradiation with or without immune checkpoint inhibition (ICI). Materials and methodsMOC1 and MOC2 tumors were inoculated in the right hind leg of each mouse (C57BL/6J, n=159). Single-dose irradiation with X-rays or protons and administration of anti-PDL1 started when the tumors reached 200 mm3. Doses of 5-30 Gy were given. Time-dependent tumor volume data were analyzed with a regression model yielding the growth rate {gamma} without irradiation and the reduction in growth rate per dose {eta}. Relative biological effectiveness (RBE) was calculated as the ratio of {eta} for X-rays to that of protons. Synergy between radiation and ICI was estimated as the ratio of {eta}s. ResultsMOC2 tumors grew faster and were more radioresistant than MOC1 tumors. ICI reduced the growth rate for MOC1 with 20{+/-}2% compared to controls, while no reduction was seen for MOC2. RBE for MOC1 wo/w ICI was 0.89{+/-}0.04 and 0.93{+/-}0.06, respectively, while it was 1.15{+/-}0.12 and 1.60{+/-}0.17, respectively, for MOC2. Combination synergy for X-rays was 1.22{+/-}0.08 and 0.96{+/-}0.11 in MOC1 and MOC2, respectively, while was it 1.27{+/-}0.06 and 1.33 {+/-}0.13, respectively, for protons. ConclusionsRBE for protons was dependent on use of ICI and tumor type. A greater synergy may be achieved when combining protons with ICI compared to X-rays and ICI.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Timing anti-PD-L1 checkpoint blockade immunotherapy to enhance tumor irradiation
Seung Young Lee, Joanna Pagacz, … Stephen J. Kron·CancersPeer-reviewed·Jan 24, 2025
- CD47 blockade enhances immunoradiotherapy response in head and neck squamous cell carcinoma
Abdula Monther, Riyam Al Msari, … Joseph A. Califano·bioRxiv·Jun 29, 2025
- Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model
L. Hartmann, W. Osen, … S. B. Eichmüller·bioRxiv·Jul 22, 2022
- Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition
Caroline P. Kerr, Won Jong Jin, … Zachary Scott Morris·Nature CommunicationsPeer-reviewed·Jan 26, 2026
- Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment
Jacob Gadwa, Justin Yu, … Sana D. Karam·Journal for ImmunoTherapy of CancerPeer-reviewed·Jan 1, 2025
- Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy
E. C. Patin, P. Nenclares, … K. J. Harrington·bioRxiv·Nov 8, 2023